All In Biotech

Drug Trial Radar · NCT06265545

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 458 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

458

Planned (sponsor's estimate)

Start

Feb 22, 2024

Primary completion

Jan 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.

Conditions

  • AML
  • Refractory
  • Relapsed

Interventions

  • IvosidenibDrug

    in arm 1

  • VenetoclaxDrug

    in arms 2-5

  • GilteritinibDrug

    in arm 2

  • HomoharringtonineDrug

    in arms 4 and 7

  • CytarabineDrug

    in arms 3 and 7

  • Daunorubicin/ Idarubicin /MitoxantroneDrug

    in arms 3 and 7

  • AzacitidineDrug

    in arms 1,2 , 5 and 8

  • LisaftoclaxDrug

    in arms 7 and 8

  • PI3K inhibitors, histone deacetylase inhibitors, selinexor, novel liposomal drugs, and othersDrug

    in arm 6

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complex response (CRc) rate (including CR and CRi)Time frame: up to 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Blood Hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.